Ellen Lubman

Ellen Lubman is a prominent figure in the biopharmaceutical industry, currently serving as a Strategic Advisor on the Board of Directors at GeneCentric Therapeutics, Inc. She has held this position for six years, where her insights and connections have significantly contributed to the company's strategic direction and growth.23

Professional Background

• Current Role: Lubman is also the Chief Business Officer at Werewolf Therapeutics, a role she has occupied since August 2020. In this capacity, she oversees corporate development, financial strategy, and investor relations.15
• Previous Experience: Before joining Werewolf, she was the Chief Business Officer at Impel NeuroPharma and held various leadership roles at major firms including Allergan, Bristol Myers Squibb, and Kadmon Pharmaceuticals. Her extensive experience encompasses business development, finance, and fundraising within the biopharma sector.12

Education

Ellen Lubman earned her M.B.A. from Stanford Graduate School of Business, focusing on Global Management, and holds a B.A. in Biology from Rutgers College.1

Contributions and Affiliations

In addition to her role at GeneCentric, Lubman serves on several boards, including:

• The Board of Directors at GeneCentric Therapeutics
• The Scientific Advisory Board of the Daedalus Innovation Fund at Weill Cornell
• The Board of Directors of Gilda's Club NYC.14

Her leadership and strategic insights have been pivotal in advancing innovative cancer therapies and supporting emerging biopharma companies.